A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients with Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 2000
- Registration Number
- NCT06792994
- Locations
- 🇩🇪
University Hospital Cologne, Cologne, Germany
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients with High Risk CLL
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 650
- Registration Number
- NCT05197192
- Locations
- 🇩🇪
Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany
🇩🇪DRK Kliniken Berlin Köpenick, Berlin, Germany
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
Efficacy of Acalabrutinib in Very Old or Frail Patients with Treatment-naïve or Relapsed/Refractory CLL
- Conditions
- Chronic Lymphoid Leukemia
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 53
- Registration Number
- NCT04883749
- Locations
- 🇩🇪
Universitaetsklinikum Essen, Essen, Germany
🇩🇪Onkologische Kooperation Harz, Goslar, Germany
🇩🇪OncoResearch Lerchenfeld, Hamburg, Germany
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
- Conditions
- Chronic Lymphoid Leukemia
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 897
- Registration Number
- NCT04608318
- Locations
- 🇩🇪
Klinikum rechts der Isar - Technische Universitaet Muenchen, München, Germany
🇳🇱Franciscus Vlietland, Schiedam, Netherlands
🇸🇪Hallands Sjukhus, Varberg, Sweden
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients with Relapsed/refractory CLL
- Conditions
- Chronic Lymphoid Leukemia
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 42
- Registration Number
- NCT04515238
- Locations
- 🇩🇪
Onkologische Schwerpunktpraxis, Esslingen, Germany
🇩🇪Hamatologische/Onkologische Gemeinschaftspraxis, Augsburg, Germany
🇩🇪Universitätsklinik Köln, Köln, Germany
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation
- Conditions
- Richter Transformation
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 83
- Registration Number
- NCT04271956
- Locations
- 🇦🇹
Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇩🇪Charité Berlin, Berlin, Germany
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL
- Conditions
- Chronic Lymphoid Leukemia
- Interventions
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 46
- Registration Number
- NCT03787264
- Locations
- 🇩🇪
Gemeinschaftspraxis Hämatologie Onkologie, Dresden, Germany
🇩🇪Universitatsklinik Carl Gustav Carus, Dresden, Germany
🇩🇪Praxis fuer Haematologie und Onkologie, Koblenz, Germany
Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation
- Conditions
- Chronic Lymphocytic LeukemiaRichter's Transformation
- Interventions
- Biological: Obinutuzumab
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 3
- Registration Number
- NCT03153514
- Locations
- 🇩🇪
Universitätsklinikum Leipzig, Leipzig, Germany
🇩🇪Universitätsklinikum Magdeburg, Magdeburg, Germany
🇩🇪Universitätsklinikum Essen, Essen, Germany
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 926
- Registration Number
- NCT02950051
- Locations
- 🇮🇱
Kaplan Medical Center, Rechovot, Israel
🇳🇱Canisius-Wilhelmina ZH, Nijmegen, Netherlands
🇳🇱Antonius Ziekenhuis Sneek, Sneek, Netherlands
Registry of the German CLL Study Group
- Conditions
- NK-LGL LeukemiaSLLT-LGL LeukemiaCLLRichter´s TransformationLeukemia, Prolymphocytic, T-CellHCLLeukemia, Prolymphocytic, B-Cell
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 8000
- Registration Number
- NCT02863692
- Locations
- 🇩🇪
BAG Freiberg-Richter, Jacobasch, Wolf, Illmer, Dresden, Sachsen, Germany